Effect of glycolipids of Leishmania parasites on human monocyte activity. Inhibition by lipophosphoglycan.
Lipophosphoglycan (LPG) and glycosyl phosphatidylinositol Ag (GPI), are glycolipids present on the membrane of Leishmania parasites. Both glycolipids have been chemically characterized. LPG is a polysaccharide of repeating phosphorylated units linked to a phosphocarbohydrate core that is anchored to the membrane by lysoalkyl phosphatidylinositol (PI). The GPI are smaller glycolipids with a structure resembling the phosphocarbohydrate core of the LPG. They are anchored to the membrane by alkyl acyl PI. Their relative abundance, uniqueness of structure, and cellular location suggest a role in interactions of the parasites with host cells. In the present study we examined the effect of LPG and GPI on the activation of human peripheral blood monocytes. Three parameters were studied: the production of IL-1, chemotactic locomotion, and oxidative burst. We found that whereas neither GPI nor LPG directly affected monocyte activity, preincubation of the monocytes with LPG strongly inhibited further activation: The production of IL-1, after stimulation with LPS, was decreased in a dose-dependent manner. Previous incubation with LPG also inhibited chemotactic locomotion of monocytes and neutrophils in response to diacylglycerol, zymosan-activated serum, FMLP and LTB4. Luminol-dependent chemiluminiscence caused by stimulation of the monocytes with streptococci and histone was also inhibited. After fragmentation of the LPG into phosphoglycan and 1-O-alkylglycerol by phosphatidylinositol-phospholipase C, only the phosphoglycan retained inhibitory activity. No difference in inhibitory activity was found between LPG prepared from Leishmania major or Leishmania donovani promastigotes. These results show that the phosphoglycan of LPG inhibits the immunologic response of normal human monocytes and neutrophils, and suggest that LPG may influence the nature of the inflammatory response surrounding infected cells.
Frankenburg
S
S
Department of Dermatology, Hadassah University Hospital, Jerusalem, Israel.
Leibovici
V
V
Mansbach
N
N
Turco
S J
SJ
Rosen
G
G
D000818:Animals; D002118:Calcium / Q000494:pharmacology; D006017:Glycolipids / Q000276:immunology / Q000494:pharmacology*; D006028:Glycosphingolipids / Q000276:immunology / Q000494:pharmacology*; D017261:Glycosylphosphatidylinositols; D007213:Indomethacin / Q000494:pharmacology; D007375:Interleukin-1 / Q000096:biosynthesis*; D007891:Leishmania / Q000276:immunology*; D008262:Macrophage Activation; D009000:Monocytes / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology; D010716:Phosphatidylinositols / Q000276:immunology / Q000494:pharmacology*
D006017:Glycolipids; D006028:Glycosphingolipids; D017261:Glycosylphosphatidylinositols; D007375:Interleukin-1; D010716:Phosphatidylinositols; C008290:lipophosphonoglycan; D002118:Calcium; D007213:Indomethacin